-

Agilent Announces High-Performance Cary 3500 Flexible UV-Vis System

Expanding possibilities for pharmaceutical sample analysis

SANTA CLARA, Calif.,--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest addition to the Cary 3500 UV-Vis Series with the release of the Agilent Cary 3500 Flexible UV-Vis System. This new solution is a double-beam spectrophotometer with advanced photometric performance for diverse sample-type measurements with minimal sample preparation. The Cary 3500 UV-Vis Series can be deployed in regulated environments, specifically the pharma/biopharma industry.

The new Cary 3500 Flexible UV-Vis system offers a uniquely large sample compartment with a small footprint for analyzing a range of liquid samples and characterizing solid samples. The full Cary 3500 UV-Vis spectrophotometer series also includes a 10-year warranty xenon flash lamp, (for Cary 3500 instruments purchased from Agilent or participating partners), drastically reducing the frequency and cost of deuterium lamp replacement, and eliminating the daily warmup time.

Another key development is the enhancement of the Cary UV Workstation software. New calculations can now be saved and applied automatically to any method routinely used to reduce data processing time and calculation errors. It is accessible to new customers and existing users who want to upgrade to the latest software version. Additionally, the Cary 3500 UV-Vis spectrophotometer series, including the new UV-Vis Flexible module, can be deployed with the OpenLab software suite to help organizations achieve their data management and compliance goals.

“The Cary 3500 Flexible UV-Vis spectrophotometer is the next major step in a long history of UV-Vis innovation at Agilent,” said Geoff Winkett, vice president and general manager of Agilent’s Molecular Spectroscopy Division.

Winkett continued. “The series has been an incredible success since its introduction in 2018 and our customers—particularly those in the pharma and biopharma industries—have benefitted from the unique range of capabilities. This further strengthens our distinctive portfolio of integrated solutions under the Agilent OpenLab umbrella, from chromatography to mass spectroscopy, to UV-Vis spectroscopy.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...
Back to Newsroom